<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132823">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856478</url>
  </required_header>
  <id_info>
    <org_study_id>1200.161</org_study_id>
    <nct_id>NCT01856478</nct_id>
  </id_info>
  <brief_title>LUX-Head&amp;Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy</brief_title>
  <official_title>A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Egypt: Ministry of Health and Population</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Philippines: Department of Health</authority>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Thailand: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open-label, phase III study will be performed in patients with recurrent
      and/or metastatic head and neck cancer which has progressed after platinum-based therapy.
      The objectives of this trial are to compare the efficacy and safety of afatinib versus
      methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression free survival (PFS), defined as the time from the date of randomization to the date of progression evaluated according to RECIST 1.1 or to the date of death, whichever occurs first</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), defined as the time from the date of randomization to the date of death (regardless of the cause of death)</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response defined as complete response (CR) or partial response (PR) determined by RECIST 1.1 according to the best response to study medication</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL) will be assessed based on patient-reported questionaires</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral intake, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous bolus injection, once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>intravenous bolus injection, once weekly</description>
    <arm_group_label>methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>oral intake, once daily</description>
    <arm_group_label>afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx, which has recurred/metastasised and is not
             amenable for salvage surgery or radiotherapy.

          2. Documented progressive disease based on investigator assessment according to RECIST,
             following receipt of a cisplatin and/or carboplatin based regimen administered for
             recurrent and/or metastatic disease independent of whether patient progressed during
             or after platinum based therapy.

          3. Measurable disease according to RECIST (version 1.1).

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at Visit 2.

          5. Male and female patients age is 18 years or older

          6. Signed and dated written informed consent that is in compliance with ICH-GCP and
             local law.

        Exclusion criteria:

          1. Progressive disease within three months after completion of curatively intended
             treatment for locoregionally advanced or for metastatic head and neck squamous cell
             cancer (HNSCC).

          2. Primary tumour site nasopharynx (of any histology), sinuses, and/or salivary glands.

          3. Any other than one previous platinum based systemic regimen given for recurrent
             and/or metastatic disease. Re-challenge with the first line regimen after a temporary
             break is considered a second line regimen only in case of progression within the
             break.

          4. Prior treatment with EGFR-targeted small molecules.

          5. Treatment with any investigational drug or anti-cancer therapy less than four weeks
             prior to randomization (except palliative radiotherapy to bones to alleviate pain).

          6. Unresolved chronic toxicity, other than hearing loss, tinnitus or dry mouth, CTCAE
             grade &gt;2 from previous anti-cancer therapy or unresolved skin toxicities CTCAE grade
             &gt;1 and/or diarrhoea CTCAE grade &gt;1 caused by prior treatment with EGFR targeted
             antibodies.

          7. Previous tumour bleeding CTCAE grade =3.

          8. Requirement for treatment with any of the prohibited concomitant medications.

          9. Major surgical or planned procedure less than four weeks prior to randomization
             (isolated biopsies are not considered as major surgical procedures).

         10. Any other malignancy unless free of disease for at least five years except for:

               1. Other HNSCC of a location as described in inclusion criterion number 1

               2. Appropriately treated superficial basal cell skin cancer

               3. Surgically cured cervical cancer in situ

               4. For Korea: endoscopically cured superficial esophageal and/or gastric cancer is
                  allowed

         11. Known lesion or signs of brain metastasis.

         12. Known pre-existing interstitial lung disease (ILD).

         13. Clinically relevant cardiovascular abnormalities, as judged by the investigator, such
             as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA
             classification =III, unstable angina, myocardial infarction within six months prior
             to randomization, or poorly controlled arrhythmia.

         14. Cardiac left ventricular dysfunction with resting ejection fraction &lt;lower limit of
             normal (LLN) of investigational site (if no LLN is defined at the site the lower
             limit is 50%).

         15. Significant or recent acute gastrointestinal disorders with diarrhoea as a major
             symptom in the opinion of the investigator, e.g. Crohn's disease, malabsorption or
             CTCAE grade &gt;1 diarrhoea of any aetiology at randomization.

         16. Known HIV, active hepatitis B, active hepatitis C, and/or other known severe
             infections, including but not limited to tuberculosis, as judged by the investigator.

         17. Other significant disease that in the investigator's opinion would exclude the
             subject from the trial.

         18. Screening laboratory values:

               1. Absolute neutrophil count (ANC) &lt;1.5x10^9/l

               2. Platelet count &lt;75x10^9/l

               3. Total bilirubin &gt;1.5 times the upper limit of normal (ULN)

               4. Aspartate amino transferase (AST) or alanine amino transferase (ALT) &gt;3 times
                  the ULN (if related to liver metastases &gt;5 times the ULN)

               5. Calculated creatinine clearance &lt;50 ml/min (as evidenced by using the
                  Cockcroft-Gault formula).

         19. Women of child-bearing potential and men who are able to father a child, unwilling to
             be abstinent or to use adequate contraception during the trial and for at least six
             months after end of treatment. Adequate methods of contraception and definition of
             child-bearing potential.

         20. Pregnancy or breast feeding.

         21. Known or suspected hypersensitivity to any of the study medications or their
             excipients.

         22. Any past or present history of areca/betel-nut chewing or its derivatives for a
             cumulative duration of more than 3 months

         23. Patients unable to comply with the protocol, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1200.161.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bengbu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haerbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dakahlia</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.85202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amravati</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baroda</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bikaner</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuttack</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolkata, West Bengal</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madurai, Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nasik</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Keelung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.66003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1200.161.66002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Songkla</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Egypt</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
